# OnCo record basal-cell-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/basal-cell-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "basal-cell-carcinoma" ;
  schema:name "Basal cell carcinoma"@en ;
  schema:alternateName "BCC"@en, "Basal Cell Carcinoma of the Skin"@en, "Basal cell skin cancer"@en, "Rodent ulcer"@en, "Basalioma"@en, "Keratinocyte carcinoma, basal cell type"@en, "BCC of the skin"@en ;
  schema:description "Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."@en ;
  schema:url <https://onco.cc/cancers/basal-cell-carcinoma/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Basal-cell_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q809758> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416>, <https://doi.org/10.1056/NEJMoa1113713>, <https://www.cancer.gov/types/skin/patient/skin-treatment-pdq>, <https://doi.org/10.1002/14651858.CD003412.pub3>, <https://doi.org/10.1016/S1470-2045(13)70530-8>, <https://doi.org/10.1016/j.jid.2016.10.019>, <https://doi.org/10.1016/S1470-2045(13)70143-8>, <https://doi.org/10.1016/j.jid.2017.09.033>, <https://doi.org/10.1016/j.ejca.2014.08.018>, <https://doi.org/10.1001/archderm.136.12.1524>, <https://www.skinhealthinfo.org.uk/condition/basal-cell-carcinoma/>, <https://www.skinhealthinfo.org.uk/condition/mohs-micrographic-surgery/>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/surgery/treatment-surgery-types>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/follow-up-appointments>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/photodynamic-therapy>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/treatment/chemotherapy-cream>, <https://www.nhs.uk/conditions/non-melanoma-skin-cancer/treatment/>, <https://www.rcpath.org/resourceLibrary/g123-dataset-basal.html>, <https://www.cancerresearchuk.org/about-cancer/skin-cancer/types/basal-cell-carcinoma>, <https://doi.org/10.1111/bjd.20524>, <https://www.rcpath.org/resourceLibrary/basal-cell-tnm9.html>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-melanoma-skin-cancer/incidence>, <https://doi.org/10.1093/bjd/ljag315>, <https://doi.org/10.1002/ski2.61>, <https://doi.org/10.1111/bjd.17873>, <https://doi.org/10.1093/bjd/ljaf352>, <https://www.nhs.uk/conditions/non-melanoma-skin-cancer/symptoms/> ;
  onco:tag "gap-fill", "skin" ;
  onco:related <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/bowens-disease/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/technologies/black-salve-escharotics/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/> ;
  onco:targets <https://onco.cc/targets/smoothened/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/drugs/aminolevulinic-acid/>, <https://onco.cc/drugs/nicotinamide/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/philogen-s-p-a/> ;
  onco:pathways <https://onco.cc/pathways/basal-cell-carcinoma-signalling/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/curettage-and-cautery/>, <https://onco.cc/terms/second-primary-skin-cancer/>, <https://onco.cc/terms/sun-protection-after-skin-cancer/>, <https://onco.cc/terms/facial-scar-after-skin-cancer/>, <https://onco.cc/terms/skin-graft-and-flap-reconstruction/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/terms/keratinocyte-cancer/>, <https://onco.cc/terms/actinic-keratosis/>, <https://onco.cc/terms/bcc-growth-pattern/>, <https://onco.cc/terms/skin-cancer-high-risk-features/>, <https://onco.cc/terms/tnm-skin-carcinoma/>, <https://onco.cc/terms/keratinocyte-cancer-counting/>, <https://onco.cc/terms/inherited-skin-cancer-syndromes/>, <https://onco.cc/terms/perineural-invasion/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/pathways/field-cancerisation/>, <https://onco.cc/terms/topical-and-destructive-treatment-bcc/>, <https://onco.cc/terms/surgical-margins-keratinocyte-cancer/>, <https://onco.cc/terms/hedgehog-inhibitor-tolerability/>, <https://onco.cc/terms/radiotherapy-for-skin-cancer/> ;
  onco:trials <https://onco.cc/trials/nct06050122/>, <https://onco.cc/trials/mohs-versus-excision-facial-bcc/>, <https://onco.cc/trials/sins-trial/>, <https://onco.cc/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/>, <https://onco.cc/trials/scin-trial/>, <https://onco.cc/trials/mal-pdt-versus-surgery-nodular-bcc/>, <https://onco.cc/trials/mal-pdt-versus-cryotherapy-superficial-bcc/>, <https://onco.cc/trials/avril-surgery-versus-radiotherapy-bcc/>, <https://onco.cc/trials/stevie/>, <https://onco.cc/trials/vismoneo/>, <https://onco.cc/trials/cemiplimab-advanced-bcc/>, <https://onco.cc/trials/patidegib-gel-gorlin-phase-2/> ;
  onco:pipeline <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/vismodegib/> ;
  onco:standardOfCare <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/terms/curettage-and-cautery/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/methyl-aminolevulinate/>, <https://onco.cc/drugs/aminolevulinic-acid/>, <https://onco.cc/terms/cryoablation/>, <https://onco.cc/technologies/photodynamic-therapy-lasers/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/terms/second-primary-skin-cancer/>, <https://onco.cc/terms/sun-protection-after-skin-cancer/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/pathways/field-cancerisation/>, <https://onco.cc/terms/topical-and-destructive-treatment-bcc/>, <https://onco.cc/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/>, <https://onco.cc/trials/sins-trial/>, <https://onco.cc/trials/mal-pdt-versus-cryotherapy-superficial-bcc/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/trials/mal-pdt-versus-surgery-nodular-bcc/>, <https://onco.cc/trials/scin-trial/>, <https://onco.cc/terms/topical-and-destructive-treatment-bcc/>, <https://onco.cc/terms/curettage-and-cautery/>, <https://onco.cc/trials/vismoneo/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/terms/hedgehog-inhibitor-tolerability/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/trials/stevie/>, <https://onco.cc/terms/hedgehog-inhibitor-tolerability/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/technologies/hedgehog-inhibitors/>, <https://onco.cc/trials/cemiplimab-advanced-bcc/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/irae/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/sonidegib/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/terms/hedgehog-inhibitor-tolerability/> .